At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
enzastaurindrug
Likely dose
enzastaurin 1125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating enzastaurin for Ovarian Cancer and 2 related conditions. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Neoplasms, Carcinoma
CountriesUnited States
CollaboratorsGynecologic Oncology Group
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionMay 2008
Study CompletionDec 2014
TodayJul 2026
First PostedJan 11, 2007
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2008
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.5 years ago
Interventions
enzastaurindrug
1125 mg loading dose then 500 mg, oral, daily, until progressive disease